Cargando…
Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061453/ https://www.ncbi.nlm.nih.gov/pubmed/37007583 http://dx.doi.org/10.21037/atm-22-6564 |
| _version_ | 1785017295394832384 |
|---|---|
| author | Rotte, Anand |
| author_facet | Rotte, Anand |
| author_sort | Rotte, Anand |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10061453 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100614532023-03-31 Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary Rotte, Anand Ann Transl Med Editorial Commentary AME Publishing Company 2023-01-27 2023-03-15 /pmc/articles/PMC10061453/ /pubmed/37007583 http://dx.doi.org/10.21037/atm-22-6564 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Rotte, Anand Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary |
| title | Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary |
| title_full | Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary |
| title_fullStr | Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary |
| title_full_unstemmed | Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary |
| title_short | Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary |
| title_sort | predictive models for response and survival in patients treated with anti-pd-1 monotherapy or with anti-pd-1 and ipilimumab combination: editorial commentary |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061453/ https://www.ncbi.nlm.nih.gov/pubmed/37007583 http://dx.doi.org/10.21037/atm-22-6564 |
| work_keys_str_mv | AT rotteanand predictivemodelsforresponseandsurvivalinpatientstreatedwithantipd1monotherapyorwithantipd1andipilimumabcombinationeditorialcommentary |